- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Hamlet BioPharma AB (HAMLETb)
Track the Hamlet BioPharma share price today and view real-time HAMLETb share price data, including charts, technicals, and key financials. View the HAMLETb premarket stock price ahead of the market session or assess the after hours quote. Explore HAMLETb stock price movements, trading volume, and market activity across the TE exchange.
What Is the Hamlet BioPharma Stock Price Today?
The Hamlet BioPharma stock price today is 4.79.
What Is the Stock Symbol for Hamlet BioPharma?
The stock symbol for Hamlet BioPharma is ""HAMLETb.""
What Stock Exchange Does Hamlet BioPharma Trade On?
Hamlet BioPharma is listed and trades on the Spotlight stock exchange.
Is Hamlet BioPharma a Good Stock to Buy?
Determining whether Hamlet BioPharma or any stock is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the HAMLETb quote. (ISIN: SE0015661152)
What Is the Hamlet BioPharma Stock Price Today?
The Hamlet BioPharma stock price today is 4.79.
What Is the Stock Symbol for Hamlet BioPharma?
The stock symbol for Hamlet BioPharma is ""HAMLETb.""
What Stock Exchange Does Hamlet BioPharma Trade On?
Hamlet BioPharma is listed and trades on the Spotlight stock exchange.
Is Hamlet BioPharma a Good Stock to Buy?
Determining whether Hamlet BioPharma or any stock is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the HAMLETb quote. (ISIN: SE0015661152)
Spotlight
Currency in SEK
4.79
+0.01(+0.31%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
4.35
5.20
52 wk Range
4.35
8.96
Trading near 52-week Low
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
4.355.20
52 wk Range
4.358.96
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
HAMLETb Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Short term obligations exceed liquid assets
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
Hamlet BioPharma AB Earnings Call Summary for Q4/2026
- Hamlet BioPharma raised 25.7M SEK via warrant exercises, extending cash runway into 2027 at current 3.5M SEK quarterly burn rate.
- Company plans Phase III bladder cancer trials in Q4 2026; Alpha1H showed 82% response rate at higher dose in Phase II study.
- Management reports positive talks with German partner; due diligence complete but no partnership timeline or terms disclosed yet.
- Shares fell 1.77% to $0.64; InvestingPro rates stock overvalued with weak financial health score despite strong 3.12 current ratio.
- CEO emphasized diversified pipeline reduces risk vs. single-asset biotechs; infection program Phase II showed reduced UTI recurrence.
Last Updated: 28/08/2026, 08:42 pm
Read Full TranscriptEarnings
Latest Release
28/08/2026
EPS / Forecast
-0.09 / --
Revenue / Forecast
1.71K / --
Compare HAMLETb to Peers and Sector
Metrics to compare | HAMLETb | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipHAMLETbPeersSector | |
|---|---|---|---|---|
P/E Ratio | −20.4x | −2.6x | −0.2x | |
PEG Ratio | −5.41 | −0.19 | 0.00 | |
Price/Book | 57.4x | 2.6x | 2.6x | |
Price / LTM Sales | 20,715.1x | 352.8x | 2.8x | |
Upside (Analyst Target) | - | 163.1% | 63.4% | |
Fair Value Upside | Unlock | 21.8% | 9.5% | Unlock |
Hamlet BioPharma AB (publ) engages in the development of drugs for the treatment and prevention of cancer and infections in Sweden. The company is developing Alpha1H for the treatment of bladder cancer; and IL-1 receptor antagonist (anakinra) for the treatment of bladder pain syndrome and recurrent acute cystitis that are in Phase II clinical trials, as well as Alpha1H for the treatment of brain tumor; Hamlet for the treatment of colon and rectal cancer and oral cancer; RNA Pol II inhibitor – protein for preventive anti-inflammatory and antibacterial effects; RNA Pol II inhibitor – bacteria for prevention of inflammation and treatment of infection; IRF7 inhibitor, siRNA for prevention of inhibits severe bacterial infections; and Anti-TBC peptide for prevention of pulmonary tuberculosis that are in preclinical stage. It has a collaboration agreement with University of Iowa for development of Alpha1H for patients with severe bladder cancer. Hamlet BioPharma AB (publ) was formerly known as Hamlet Pharma AB (publ) and changed its name to Hamlet BioPharma AB (publ) in August 2023. The company was incorporated in 1999 and is based in Lund, Sweden. Hamlet BioPharma AB (publ) operates as a subsidiary of Linnane Pharma AB.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Hamlet BioPharma (HAMLETb) Stock Price Today?
The Hamlet BioPharma stock price today is 4.79 SEK.
What Stock Exchange Does Hamlet BioPharma Trade On?
Hamlet BioPharma is listed and trades on the Spotlight Stock Market.
What Is the Stock Symbol for Hamlet BioPharma?
The stock symbol for Hamlet BioPharma is "HAMLETb."
What Is the Hamlet BioPharma Market Cap?
As of today, Hamlet BioPharma market cap is 1.13B SEK.
What Is Hamlet BioPharma's Earnings Per Share (TTM)?
The Hamlet BioPharma EPS (TTM) is -0.30.
From a Technical Analysis Perspective, Is HAMLETb a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Hamlet BioPharma Stock Split?
Hamlet BioPharma has split 2 times.
How Many Employees Does Hamlet BioPharma Have?
Hamlet BioPharma has 6 employees.
What is the current trading status of Hamlet BioPharma (HAMLETb)?
As of 13/11/2026, Hamlet BioPharma (HAMLETb) is trading at a price of 4.79 SEK, with a previous close of 4.80 SEK. The stock has fluctuated within a day range of 4.35 SEK to 5.20 SEK, while its 52-week range spans from 4.35 SEK to 8.96 SEK.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.